This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
TEL AVIV, Israel,
July 5, 2012 /PRNewswire/ --
InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, announced today that
Craig Shore, Chief Financial Officer, will present at the 7
th Annual JMP Securities Healthcare Conference on
July 12th in
New York City.
Date: Thursday, July 12, 2012
Time: 3 PM
Location: Chelsea Room, The Peninsula Hotel, 700 5th Avenue, New York, NY.
About the JMP Securities Healthcare Conference
th Annual JMP Securities Healthcare Conference will take place at the Peninsula Hotel in
July 12th - 13
th. This institutional investor forum will feature more than 100 publicly traded and privately held companies in the life sciences field.
JMP Securities is a full-service investment bank that provides equity research, institutional brokerage and investment banking services to growth companies and their investors. The firm specializes in four broad growth industries: Technology, Healthcare, Financial Services and Real Estate. JMP's research department covers primarily small and mid-cap public companies
Attendance at this event is restricted to clients of JMP Securities. For full event details and registration information, please click here:
About InspireMD, Inc.
InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard
™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is listed on the OTC BB under the ticker symbol "NSPR".
About MGuard™Coronary Stent
MGuard™ combines a coronary stent merged with an embolic protection specifically designed for acute MI patients. The embolic protection is comprised of an ultra-thin polymer micron net that is integrated with the stent. The MGuard™ is designed to provide outstanding and lifelong embolic protection, without affecting deliverability. MGuard™ is CE Mark approved. Mesh-based protection is now recommended for use in the recent Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC).